Korea Medical Tourism Statistics 2024: 1.17 Million Patients and Growing
Korea Medical Tourism Statistics 2024: 1.17 Million Patients and Growing
South Korea’s medical tourism industry hit a milestone in 2024, welcoming approximately 1.17 million international patients, a figure that cements its position as one of the fastest-growing medical tourism destinations in the world. This represents a full recovery from the pandemic-era collapse and a significant increase over the pre-COVID peak of approximately 497,000 patients in 2019.
The revenue picture is equally striking. Medical tourism generated an estimated $2.47 billion (KRW 3.4 trillion) in 2024, according to data from the Korea Health Industry Development Institute (KHIDI) and the Ministry of Health and Welfare. Per-patient spending averaged approximately $2,100, though this figure varies enormously by treatment type. A wellness checkup patient may spend $500-$1,000, while a cancer treatment or organ transplant patient may spend $50,000 or more.
This article examines the data behind Korea’s medical tourism boom: where the patients come from, what they come for, how Korea compares to competing destinations, and what the trajectory looks like.
The Numbers: 2024 in Context
| Year | International Patients | Revenue (USD) | Year-over-Year Growth |
|---|---|---|---|
| 2009 | 60,201 | $55M | — (program launch) |
| 2012 | 159,464 | $116M | +30% |
| 2015 | 296,889 | $538M | +10% |
| 2018 | 378,967 | $759M | +8% |
| 2019 | 497,464 | $953M | +31% |
| 2020 | 71,737 | $181M | -86% (COVID) |
| 2021 | 60,506 | $201M | -16% |
| 2022 | 248,882 | $552M | +311% |
| 2023 | ~600,000 | $1.3B | +141% |
| 2024 | ~1,170,000 | $2.47B | +95% |
The 2024 figure represents a compound annual growth rate (CAGR) of approximately 21% since 2009, when Korea formally launched its medical tourism program. Even excluding the pandemic years, the growth trajectory is remarkable. Korea has more than doubled its 2019 pre-pandemic peak.
Where Do the Patients Come From?
Korea’s medical tourism patient base is geographically diverse, though heavily weighted toward Asia.
Top Source Countries (2024 Estimates)
| Rank | Country | Approx. Share | Primary Treatments Sought |
|---|---|---|---|
| 1 | China | ~25% | Plastic surgery, dermatology, health checkups |
| 2 | Japan | ~12% | Health checkups, dental, dermatology |
| 3 | United States | ~8% | Health checkups, cancer treatment, plastic surgery |
| 4 | Russia/CIS | ~7% | Plastic surgery, health checkups, oncology |
| 5 | Vietnam | ~6% | Health checkups, orthopedics |
| 6 | Mongolia | ~5% | General medical, cancer treatment |
| 7 | Kazakhstan/Uzbekistan | ~5% | Cardiac, cancer, health checkups |
| 8 | Thailand | ~4% | Plastic surgery, dermatology |
| 9 | Indonesia | ~3% | Health checkups, cardiac |
| 10 | Middle East (UAE, Saudi) | ~3% | Cancer treatment, fertility, orthopedics |
Notable trends:
- China remains dominant but its share has decreased from ~35% pre-pandemic to ~25%, reflecting both diversification of Korea’s patient base and China’s own healthcare improvements.
- The US and Europe are growing fastest among high-spend segments. American and European patients tend to seek higher-value treatments (cancer care, complex surgery, full checkups) with per-visit spending 3-5 times the overall average.
- Russia and Central Asia (CIS countries) represent a significant and growing segment. Russian-speaking patients are drawn by Korea’s combination of advanced technology and (relative to Europe) affordable pricing. Several Korean hospitals, including Bucheon St. Mary’s Hospital, have Russian-licensed physicians on staff.
- The Middle East is a high-value segment despite lower volume. Government-sponsored patients from Gulf countries often seek complex cancer or cardiac treatments.
What Treatments Are Most Popular?
Korea’s medical tourism is not monolithic. The treatment mix reflects the country’s specific clinical strengths.
Treatment Categories (2024 Estimates)
| Treatment Category | Approx. Share of Patients | Approx. Share of Revenue |
|---|---|---|
| Internal medicine (including health checkups) | ~28% | ~18% |
| Plastic surgery/cosmetic | ~20% | ~12% |
| Dermatology | ~15% | ~8% |
| Orthopedics | ~7% | ~10% |
| Dentistry | ~6% | ~5% |
| Ophthalmology | ~5% | ~4% |
| Oncology | ~4% | ~15% |
| OB/GYN & fertility | ~3% | ~6% |
| Cardiac surgery | ~2% | ~8% |
| Organ transplant | ~1% | ~5% |
| Other | ~9% | ~9% |
Key observations:
-
Health checkups are the gateway. The single largest volume driver is thorough medical checkups. Korean hospitals offer executive health screening packages at $500-$3,000 that would cost $5,000-$15,000 in the US. Many patients who come for a checkup return for treatment of conditions discovered during screening.
-
Plastic surgery and dermatology combined account for about 35% of patients but only 20% of revenue. These are high-volume, lower-cost procedures. Korea’s reputation as the global capital of plastic surgery continues to drive patient numbers.
-
Oncology and cardiac surgery are low-volume but high-revenue. A single cancer patient receiving treatment at Seoul St. Mary’s Hospital or Severance Hospital may generate $50,000-$200,000 in medical spending.
-
Dental tourism is growing rapidly. Korean dental clinics offer implants and cosmetic dentistry at 50-70% less than US prices with excellent outcomes.
-
Dermatology and skincare is a uniquely Korean strength. Treatments like laser toning, HIFU, thread lifts, and full skin rejuvenation programs are a major draw, particularly for patients from Southeast Asia, Japan, and China.
How Korea Compares to Competing Destinations
Korea is not the cheapest medical tourism destination, nor the most established. Its competitive position is distinct: premium quality at moderate pricing.
Medical Tourism Comparison (2024 Data)
| Country | Annual Medical Tourists | Revenue | Avg. Spend per Patient | Key Strengths |
|---|---|---|---|---|
| Thailand | ~3.5M | $5.5B | ~$1,600 | Bumrungrad brand, affordability, wellness/spa |
| India | ~2.5M | $7.5B | ~$3,000 | Cardiac, orthopedic, affordability, English |
| Turkey | ~1.5M | $3.0B | ~$2,000 | Hair transplant, dental, geographic proximity to Europe/ME |
| South Korea | ~1.17M | $2.47B | ~$2,100 | Technology, cancer, plastic surgery, checkups |
| Singapore | ~500K | $2.5B | ~$5,000 | Premium positioning, wealthy patients, cancer |
| Malaysia | ~1.0M | $1.5B | ~$1,500 | Affordability, Islamic medical tourism |
| Mexico | ~1.5M | $2.0B | ~$1,300 | Dental, bariatric, proximity to US |
Korea’s positioning:
- Korea is more expensive than India, Thailand, or Turkey, but significantly cheaper than Singapore, Japan, the US, or Europe.
- Korea’s technological edge is its differentiator. Korean hospitals adopt new medical technology faster than virtually any country. Robotic surgery, proton therapy, advanced imaging, and AI-assisted diagnostics are widely available.
- Korea excels in specific procedures. It is arguably the world leader in plastic surgery, health screenings, and dermatology. Its cancer care and transplant surgery rival any country.
- Korea’s weakness has historically been language barriers, but this is improving rapidly. Major hospitals now have international patient centers with staff speaking English, Chinese, Russian, Arabic, Japanese, and Vietnamese.
What Is Driving Korea’s Growth?
Several factors explain why Korea’s medical tourism is growing faster than most competitors.
1. Government Investment
The Korean government has treated medical tourism as a strategic export industry since 2009. Key initiatives include:
- Korea Medical Tourism Visa (C-3-3 and G-1-10). Streamlined visa categories specifically for medical tourists and their companions.
- KHIDI (Korea Health Industry Development Institute). A government agency dedicated to promoting Korean healthcare internationally, operating offices and roadshows in target markets.
- Financial incentives for hospitals. Tax benefits and grants for hospitals that establish international patient centers and achieve international accreditation.
- Deregulation. Allowing hospitals to advertise overseas and facilitating telemedicine consultations with international patients.
2. Hospital Infrastructure
Korea has 47 JCI-accredited hospitals (as of 2024), one of the highest concentrations in Asia. Beyond accreditation, the sheer quality of hospital infrastructure is striking. Major Korean hospitals have:
- Robotic surgery suites (Da Vinci, ROSA, Mako)
- Proton and heavy-ion therapy centers
- AI-assisted diagnostic imaging
- Fully integrated electronic medical records
- International patient coordinators on staff
Hospitals like Severance Hospital (2,462 beds, Newsweek #40 globally) and Korea University Anam Hospital (5x JCI accredited, 838 beds) represent the kind of facility that international patients would struggle to access at comparable cost in any Western country.
3. K-Culture Halo Effect
The global popularity of Korean culture (K-pop, K-drama, K-beauty, Korean cuisine) has created an enormous soft-power advantage. For many potential medical tourists, particularly from Southeast Asia, China, and increasingly from the West, Korea is already an aspirational destination. The step from “I want to visit Korea” to “I will get my health checkup/cosmetic procedure in Korea” is shorter than for most competing countries.
4. Competitive Pricing Without Compromising Quality
Korea achieves its pricing advantage through a combination of factors:
- Government-regulated fee schedules keep hospital charges lower than in fully market-priced systems (US, Singapore).
- High volume allows hospitals to spread fixed costs across more patients.
- Efficient healthcare delivery. Korean hospitals are famously efficient, with shorter wait times and faster throughput than Western counterparts.
- Lower labor costs relative to the US and Western Europe, despite comparable (or superior) training.
5. Post-Pandemic Pent-Up Demand
The explosion from ~600,000 patients in 2023 to ~1.17 million in 2024 partly reflects pent-up demand. Patients who delayed treatment during 2020-2022 returned in force. However, the sustained growth trajectory suggests this is not merely a temporary rebound.
Revenue Per Treatment Type
Not all medical tourists contribute equally to the bottom line. Here is the approximate revenue breakdown by treatment type.
| Treatment | Typical Cost Range (USD) | Share of Total Revenue |
|---|---|---|
| Cancer treatment (chemo, radiation, surgery) | $15,000-$200,000 | ~15% |
| Cardiac surgery | $20,000-$80,000 | ~8% |
| Organ transplant | $50,000-$300,000 | ~5% |
| Orthopedic surgery | $8,000-$30,000 | ~10% |
| Health checkups | $500-$3,000 | ~18% |
| Plastic surgery (surgical) | $3,000-$15,000 | ~8% |
| Plastic surgery (non-surgical) | $500-$3,000 | ~4% |
| Dermatology/skincare | $200-$2,000 | ~8% |
| Dental | $500-$5,000 | ~5% |
| Fertility/IVF | $5,000-$15,000 | ~6% |
| Other | Varies | ~13% |
The takeaway: while plastic surgery and dermatology drive patient volume, the revenue engine is complex medical treatment: cancer, cardiac, transplant, and orthopedics. This is significant because it demonstrates that Korea is not merely a “cosmetic surgery destination” but a serious medical hub.
Future Projections
Based on current trends, industry analysts and KHIDI project:
- 2025 target: 1.5 million patients, $3.2 billion revenue
- 2027 target: 2.0 million patients, $5.0 billion revenue (Korean government’s stated goal)
- Long-term: Korea aims to be the #1 medical tourism destination in Asia by revenue per patient
These projections are ambitious but plausible given the growth trajectory. Key factors that could accelerate growth:
- Expanded visa-free arrangements with key source countries
- Carbon-ion therapy facility at Yonsei/Severance, attracting high-value cancer patients
- Telemedicine regulations enabling pre- and post-treatment remote consultations
- Direct airline routes from source countries to Seoul
Factors that could slow growth:
- China’s healthcare improvements reducing outbound medical travel
- Regional competition from Thailand, India, and the emerging UAE medical hub
- Exchange rate fluctuations (a stronger Korean won reduces price competitiveness)
- Geopolitical tensions affecting patient flows from certain regions
What This Means for International Patients
The data tells a clear story: Korea is no longer an emerging medical tourism destination. It is an established one, with the infrastructure, expertise, and government support to handle over a million international patients per year.
For patients considering medical treatment abroad, Korea’s value proposition is:
- Technology. Korean hospitals have equipment and capabilities that match or exceed any country, including the US.
- Outcomes. Published outcomes data from Korean hospitals (survival rates, complication rates, success rates) are consistently world-class.
- Cost. 30-70% savings versus the US for comparable treatment, depending on the procedure.
- Safety. 47 JCI-accredited hospitals, strict government regulation, and a healthcare system that the Bloomberg Health-Care Efficiency Index has repeatedly ranked among the top 5 globally.
- Access. Unlike some countries where wait times for specialists stretch into months, Korean hospitals can typically schedule international patients within 1-2 weeks of initial contact.
Interested in exploring medical treatment in Korea? We help international patients work through the system, connect with the right hospitals, and handle all logistics.